We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Brush Biopsy Test Detects Oral Cancer without Surgery

By LabMedica International staff writers
Posted on 18 Jan 2024

Oral squamous cell carcinoma, the most common type of oral cancer and globally the ninth most prevalent cancer, currently relies on surgical biopsies for diagnosis. More...

This additional referral step poses the risk of losing patients who may not return for follow-up until the cancer has progressed to advanced, more challenging stages. Additionally, surgical biopsies can be problematic as they often collect a mix of cell types, complicating the analysis, and creating the risk of spreading cancerous cells to other parts of the mouth. General blood tests looking for cancer's genetic signals also have limitations, as they do not specify the tumor’s location, preventing quick initiation of treatment after detection. Now, a new test that allows dentists to screen for oral squamous cell carcinoma with a simple brush could early detection of oral cancer without surgery.

The diagnostic kit, created by researchers at the University of Illinois Chicago (Urbana, IL, USA), employs a small brush to gather cells from potential cancerous lesions in the mouth. It operates by detecting tiny segments of genetic material, known as microRNA, which regulate gene expression. Studies conducted by the researchers found a unique expression signature of 40 microRNA sequences that can accurately differentiate between a tumor and normal tissue with more than 90% accuracy. Significantly, their test also successfully works with epithelial cells, the outermost layer in the patient’s mouth. These cells can be quickly and painlessly collected in under a minute by a dentist or nurse using gentle brushing. After collection, the brush is placed in a solution tube and sent to a lab for microRNA analysis, with results being available within days using the current test version.

The brush biopsy test offers several advantages, including specific targeting of the tissue site. The researchers anticipate that this new test will simplify screening, especially in populations that lack regular dental care or are more prone to oral squamous cell carcinoma. For instance, Black men, who experience significantly lower survival rates with this disease compared to other racial groups, could benefit greatly. The potential for using this technology in non-clinical settings opens up opportunities for earlier cancer detection in high-risk groups. Additionally, this approach could eventually help diagnose other oral diseases, each identified by unique microRNA signatures.

“We were the first to observe that brush biopsy samples actually work quite well when you use microRNA,” said Guy Adami of the UIC College of Dentistry. “All you need is a good light and the brushes.”

“There are 600 different diseases that occur in the mouth, and a number of these have already been characterized with microRNAs,” added Dr. Joel Schwartz of the UIC College of Dentistry. “We could use the same approach and really have a profound impact on these kinds of disease.”

Related Links:
University of Illinois Chicago


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.